Skip to content
- T cell-macrophage interactions in tuberculosis: What we’ve got here is failure to communicate. Mortensen R, Arlehamn CSL, Coler RN, Gerner MY, Goletti D, Lewinsohn DA, Modlin RL, Musvosvi M, Rengarajan J, Urdahl KB, Walzl G, Behar SM, Barber DL; Collaboration for Tuberculosis Vaccine Discovery – Conventional T cells Research Community, Gates Foundation. J Intern Med. 2026 Jan;299(1):44-65. doi: 10.1111/joim.70028. Epub 2025 Nov 22.
- Efficient recombinant protein secretion in Mycobacterium smegmatis: A valuable platform for protein production involved in biomedical development targeting mycobacterial diseases. Takeuchi H, Mizuno S, Matsuo K. J Biotechnol. 2026 Jan;409:148-156. doi: 10.1016/j.jbiotec.2025.10.013. Epub 2025 Nov 1.
- TZ1391: a computationally designed circular mRNA multi-epitope vaccine candidate against Mycobacterium tuberculosis via TLR3 immunomodulation. Ali A, Alamri A, Mishra VK, Utegenova A, Askarova G, Baiduissenova A, Dusmagambetova A. BMC Immunol. 2026 Jan 2. doi: 10.1186/s12865-025-00795-4. Epub ahead of print.
- Development of Exclusive and Efficient Intranasal or Pulmonary Dosing Methods for a Dry Powder Tuberculosis Vaccine for Use in Nonhuman Primates. Chen JZ, Tavernini S, Aisenstat M, Duong K, Wang H, McCollum J, McClary WD, Gerhardt A, Kuehl PJ, Martin AR, Vehring R, Fox CB. J Aerosol Med Pulm Drug Deliv. 2026 Jan 2. doi: 10.1177/19412711251383716. Epub ahead of print.
- Mucosal Adenovirus-Vectored Rv2299c Vaccine Protects Against Tuberculosis by Inducing Trained Immunity in Dendritic Cells and Polyfunctional T Cells. Wang H, Xie S, Huang S, Huang X, Zhang Y, Wu J, Fan XY, Hu Z. Vaccines (Basel). 2026 Jan 2;14(1):55. doi: 10.3390/vaccines14010055.
- Targeting mycobacterial PPE65 protein to develop a multi-epitope vaccine candidate against tuberculosis. Swargiary M, Qureshi R, Jyotisha, Qureshi IA. Int J Biol Macromol. 2026 Jan 2:150012. doi: 10.1016/j.ijbiomac.2025.150012. Epub ahead of print.
- 1-rpfBor pcDNA3.1-rpfD recombinant DNA prevents Mycobacterium tuberculosis infection in BALB/c mice. Rukmana A, Adiyaksa J, Sjatha F, Dwina Billianti Y, Agung Pratama W, Nolia E. J Immunoassay Immunochem. 2026 Jan 5:1-19. doi: 10.1080/15321819.2025.2611008. Epub ahead of print.
- Intranasal BCG vaccination induces systemic and pulmonary mucosal immune responses against tuberculosis in a goat model. Cuenca-Lara P, Blay-Benach M, Cervera Z, Moraleda J, Sevilla IA, Garrido JM, Singh M, López-Soria S, Vidal E, Domingo M, Pérez de Val B. Front Immunol. 2026 Jan 2;16:1740197. doi: 10.3389/fimmu.2025.1740197.
- Semi-Synthesis of Immunogenic Mycobacterial Lipoproteins via Aryl Selenoester-Mediated Expressed Protein Ligation. Kambanis L, Dilly JJ, Maxwell JWC, Stockdale S, Fry SE, Harrison K, Byrne SN, Ashhurst AS, Kulkarni SS, Payne RJ. Angew Chem Int Ed Engl. 2026 Jan 9;65(2):e19647. doi: 10.1002/anie.202519647. Epub 2025 Nov 10.
- BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis. Maerz MD, Makatsa MS, Bucsan AN, Sutton MS, Bishop E, Tian Z, Layton ED, Roederer M, Shalek AK, Seder RA, Scriba TJ, Wang C, Darrah PA, Seshadri C. Cell Rep Med. 2026 Jan 12:102536. doi: 10.1016/j.xcrm.2025.102536. Epub ahead of print.
- A CLOCK-targeting lncRNA induces trained immunity against tuberculosis. Yu S, Chai Q, Lu Z, Qiu C, Zhong Y, Wang Y, Lei Z, Qiang L, Fang Y, Zhang X, Li B, Gao M, Zhang L, Cheng G, Wang J, Liu CH, Pang Y. Cell Host Microbe. 2026 Jan 14;34(1):68-85.e13. doi: 10.1016/j.chom.2025.12.002. Epub 2025 Dec 30.
- BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis. Maerz MD, Makatsa MS, Bucsan AN, Sutton MS, Bishop E, Tian Z, Layton ED, Roederer M, Shalek AK, Seder RA, Scriba TJ, Wang C, Darrah PA, Seshadri C. Cell Rep Med. 2026 Jan 20;7(1):102536. doi: 10.1016/j.xcrm.2025.102536. Epub 2026 Jan 12.
- Antibodies in tuberculosis: functional capacity as key determinant. van Meijgaarden KE, Grace PS, Freund NT, Achkar JM, Lindenstrøm T, Tan J, Chan J, King CG, Ottenhoff THM, Joosten SA; CTVD B cell group. Infect Immun. 2026 Jan 21:e0039425. doi: 10.1128/iai.00394-25. Epub ahead of print.
- Targeting the lung innate pathways during tuberculosis can improve vaccine-induced protection via Th17 responses in diversity outbred mice. Ahmed M, Das S, Rosa BA, Rangel Moreno J, Kaushal D, Mitreva M, Khader SA. mBio. 2026 Jan 20:e0323225. doi: 10.1128/mbio.03232-25. Epub ahead of print.
- CD8+ lymphocytes in immunity against tuberculosis. Li J, Simonson AW, Flynn JL. J Immunol. 2026 Jan 21;215(1):vkaf268. doi: 10.1093/jimmun/vkaf268.
- Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. Seshadri C, Flynn JL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ, Jamrozik E, Fortune SM, Kublin JG. Lancet Microbe. 2026 Jan 23:101278. doi: 10.1016/j.lanmic.2025.101278. Epub ahead of print.
- Rare variable tuberculosis antigens induce predominant Th17 responses in human infection. Ogongo P, Wassie L, Tran A, Columbus D, Huffaker J, Sharling L, Ouma G, Ouma SG, Bobosha K, Lindestam Arlehamn CS, Gandhi NR, Auld SC, Rengarajan J, Day CL, Queiroz A, Araújo-Pereira M, Fukutani E, Andrade BB, Altman JD, Blumberg HM, Ernst JD. JCI Insight. 2026 Jan 27:e202134. doi: 10.1172/jci.insight.202134. Epub ahead of print.
- TB vaccine development: monitoring international patent filings to anticipate access challenges. Pignataro MF, Scopel CT, Bacigalupo ML, Frick M, Kondratyuk S, Chaves GC. Front Public Health. 2026 Jan 16;13:1726153. doi: 10.3389/fpubh.2025.1726153.
- Discovery of a multi-epitope tuberculosis vaccine targeting phospholipase C virulence factors: an insilico approach. Maru B, Shah A. Biotechnol Lett. 2026 Jan 27;48(1):25. doi: 10.1007/s10529-026-03690-z.
- Pregnant women’s attitudes and intentions toward tuberculosis, malaria, group B streptococcus, and respiratory syncytial virus vaccines in pregnant: Findings from a cross-sectional study of pregnant women living in Brazil, Ghana, Kenya, and Pakistan. Limaye R, Schue J, Fesshaye B, Singh P, Miller E, Souza R, Jessani S, Temmerman M, Badzi CD, Sauer M, Brizuela V, Karron R. PLOS Glob Public Health. 2026 Jan 28;6(1):e0004562. doi: 10.1371/journal.pgph.0004562.
- Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa. Thomas KA, Okoro C, Ntshiqa T, Damovsky V, Goldberg D, Ramokhoase O, Clark RA, Jassat W, Churchyard GJ, Abdullah F, Kubjane M, Seeley J, Charalambous S, White RG. PLOS Glob Public Health. 2026 Jan 30;6(1):e0005047. doi: 10.1371/journal.pgph.0005047.
- A novel mi3 VLP nanoparticle vaccine displaying ESAT-6 -PPE57 -PPE68 -EsxV antigens exhibits superior immunogenicity and Mycobacterium tuberculosis growth inhibition. Chen Q, Huang N, Liao M, Zhang X, Aiman S, Li S, Chen M, Wang J, Ouyang P, Zhang Y, Zhu J, Huang K, Xu G. Int Immunopharmacol. 2026 Jan 31;173:116264. doi: 10.1016/j.intimp.2026.116264. Epub ahead of print. PMID: 41621381.
